A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Kissei Pharmaceutical Co., Ltd.

Overview

The purpose of this study is to investigate the safety and efficacy for 52-week dosing of JR-131 in renal anemia patients with chronic kidney disease (CKD).

Study Type

INTERVENTIONAL

Masking

NONE

Conditions

Anemia

Interventions

JR-131DRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients being treated with erythropoiesis stimulating agent. Exclusion Criteria: * Patients having complication or history of a cardiovascular / lung / brain infarction. * Patients having a pronounced hemorrhagic lesion.

Locations (1)

Unnamed facility

Multiple Locations, Japan

Outcomes

Primary Outcomes

Measure adverse events

Time frame: 52 weeks

Secondary Outcomes

Hemoglobin level

Time frame: 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.